Business Description
Galmed Pharmaceuticals Ltd
ISIN : IL0011313900
Total Employee Number:
6Description
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.87 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 75 | |||||
3-Year EPS without NRI Growth Rate | 75.7 | |||||
3-Year FCF Growth Rate | 77.7 | |||||
3-Year Book Growth Rate | -70.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 32.88 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 48.68 | |||||
9-Day RSI | 46.28 | |||||
14-Day RSI | 45.7 | |||||
3-1 Month Momentum % | -8.08 | |||||
6-1 Month Momentum % | -32.13 | |||||
12-1 Month Momentum % | -71.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.71 | |||||
Quick Ratio | 7.71 | |||||
Cash Ratio | 7.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -260.9 | |||||
Shareholder Yield % | -185.48 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -64.44 | |||||
ROA % | -56.79 | |||||
ROIC % | -481.75 | |||||
3-Year ROIIC % | -567.41 | |||||
ROCE % | -53.86 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.25 | |||||
Price-to-Tangible-Book | 0.25 | |||||
EV-to-EBIT | 1.23 | |||||
EV-to-EBITDA | 1.23 | |||||
EV-to-Forward-Revenue | 294.76 | |||||
EV-to-FCF | 1.48 | |||||
| Price-to-Net-Current-Asset-Value | 0.25 | |||||
| Price-to-Net-Cash | 0.26 | |||||
Earnings Yield (Greenblatt) % | 81.3 | |||||
FCF Yield % | -189.73 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GLMD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Galmed Pharmaceuticals Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.17 | ||
| Beta | 2.9272 | ||
| 3-Year Sharpe Ratio | -0.91 | ||
| 3-Year Sortino Ratio | -1.22 | ||
| Volatility % | 65.17 | ||
| 14-Day RSI | 45.7 | ||
| 14-Day ATR ($) | 0.059143 | ||
| 20-Day SMA ($) | 0.54802 | ||
| 12-1 Month Momentum % | -71.18 | ||
| 52-Week Range ($) | 0.4111 - 2.03 | ||
| Shares Outstanding (Mil) | 7.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Galmed Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Galmed Pharmaceuticals Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-26 | In 121 days | ||
| General meeting for 2025 | 2026-10-28 16:00 | In 93 days | ||
| Second quarter earnings results for 2026 | 2026-08-28 | In 31 days | ||
| First quarter earnings results for 2026 | 2026-07-31 | In 3 days | ||
| Annual report for 2025 | 2026-03-31 | 0.47 (-1.05%) | ||
| Third quarter earnings results for 2025 | 2025-11-26 | 0.82 (-5.53%) | ||
| General meeting for 2024 | 2025-10-28 16:00 | 1.38 (-2.82%) | ||
| Second quarter earnings results for 2025 | 2025-08-28 | 1.39 (-1.42%) | ||
| First quarter earnings results for 2025 | 2025-05-22 | 1.37 (-2.14%) | ||
| Annual report for 2024 | 2025-04-02 | 1.42 (+2.16%) |
Show
Entries
Galmed Pharmaceuticals Ltd Frequently Asked Questions
What is Galmed Pharmaceuticals Ltd(GLMD)'s stock price today?
The current price of GLMD is $0.53. The 52 week high of GLMD is $2.03 and 52 week low is $0.41.
When is next earnings date of Galmed Pharmaceuticals Ltd(GLMD)?
The next earnings date of Galmed Pharmaceuticals Ltd(GLMD) is 2026-07-31 Est..
Does Galmed Pharmaceuticals Ltd(GLMD) pay dividends? If so, how much?
Galmed Pharmaceuticals Ltd(GLMD) does not pay dividend.
Guru Commentaries on NAS:GLMD
No articles.
Press Release
Articles on Galmed Pharmaceuticals Ltd
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers